












PGx Case Study

Data is based on 189 patients* that were tested for pharmacogenomics (PGx) by Precision Health Solutions



-  29 patients identified
-  47 patients identified
-  54 patients identified
-  59 patients identified

| Icon | Stratification Category | Description |
|--|---------------------------------|--|
|  | Immediate Attention | Immediate attention recommends the provider considers these patients prior to other categories due to the level of urgency of some of the drug-drug and drug-gene interactions observed by the pharmacist. |
|  | High-Risk Management | Patients with greater than 2 drug-drug and drug-gene interactions requiring therapy medication or recommending therapy modification. |
|  | Moderate-Risk Management | Patients with 1-2 drug-drug interactions and drug-gene interactions needing monitoring, possible alternative therapy, or dosing adjustment. |
|  | Low-Risk Management | Patients with 1 or no drug-drug and drug-gene interactions with no recommendations. |

*The data is based on the sample size (189 patients, age 65+) that received a pharmacogenomics (PGx) test while at long term care facilities in Florida. These patients were identified by their ordering physician due to potential adverse drug reactions (ADRs) or polypharmacy. Results were analyzed by a licensed pharmacogenomics pharmacist to identify stratification categories for precision medication management. Dated January-March 2023.